The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company’s antiviral Paxlovid.
After reports said some patients who took Paxlovid rebounded and started feeling symptoms again, the CEO told Bloomberg that patients can take another course, “like you do with antibiotics.”
The FDA isn’t on board with the suggestion.
“There is no evidence of benefit at this time for a longer course of treatment … or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course,” John Farley, M.D., director of the Office of Infectious Diseases, said in a post.
I question if there is any evidence of benefit at all! You may, or may not, recall that Paxlovid was granted EAU. And only an EAU. Emergency Use Authorization. Same as the experimental jabs.
Pfizer received an emergency use authorization from the FDA in December to sell its antiviral, the first of its kind to fight COVID-19. Since then, the U.S. has ordered 20 million courses and is working to bolster the pill’s availability. The drug is heavily endorsed by the Biden administration…
The pill is prescribed as a five-day course, and its directions read that it is “not authorized for use for longer than 5 consecutive days.”
It’s probably the triple jabbed and their break through cases lapping up the Paxlovid.
PS:
1st: Elderly family member, unjabbed, tested positive for Covid. Very minor symptoms (low grade fever, cough, runny nose) Got over it in under a week. Congregate setting. Isolated for a short time. Tested negative about then days later. And is fine. This family member is older then the first mentioned case.
2nd: An elderly family member, triple jabbed, has tested positive for Covid and is now isolating. It’s a congregate setting situation.
Both are woman. Neither are overweight or diabetic. One is on blood pressure meds, unsure about the other. 2nd triple jabbed. First unjabbed. Both had the same mild symptoms.